Immuron (IMRN) AI Stock Analysis

• Market Cap: $12.41M
• Dividend Yield: N/A
• Average Volume (3M): 433.85K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.32
• Revenue Growth: 82.77%
• EPS Growth: -87.95%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 6,705,499
• 10 Day Avg. Volume: 1,254,906
• 30 Day Avg. Volume: 433,854
• PEG Ratio: 0.34
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.00
• Price Target Upside: 14.29% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: $1.50 ▼(-14.29%Downside)

Immuron's overall stock score is primarily impacted by its strong revenue growth yet significant challenges in profitability and cash flow, leading to liquidity concerns. The technical analysis presents a neutral outlook with slight downward pressure. The valuation remains unattractive due to a negative P/E ratio and no dividend yield, further weighing down the score.

Immuron Business Overview & Revenue Model

Company Description

Immuron Limited (IMRN) is a biopharmaceutical company focused on the research, development, and commercialization of oral immunotherapy products for the treatment of gut-mediated diseases. The company's core products are based on its proprietary technology platform that utilizes colostrum-derived polyclonal antibodies. Immuron's primary product, Travelan, is designed to reduce the risk of travelers' diarrhea and is marketed in several countries. The company is also involved in developing treatments for non-alcoholic steatohepatitis (NASH) and Clostridium difficile infections.

How the Company Makes Money

Immuron makes money primarily through the sale of its commercial product, Travelan, which is sold over-the-counter to travelers seeking to prevent travelers' diarrhea. Revenue is generated from direct sales, distribution agreements, and licensing deals across various international markets. Additionally, Immuron invests in research collaborations and partnerships aimed at expanding its product portfolio, including potential treatments for NASH and Clostridium difficile infections. These partnerships may offer milestone payments and royalties based on the success of development and commercialization efforts. The company's revenue streams are thus a combination of product sales, licensing, and strategic partnerships.

Immuron Financial Statement Overview

Summary

Immuron demonstrates strong revenue growth with a 171.7% increase, but profitability remains a major challenge due to negative net profit margin and high operating expenses. The balance sheet shows financial stability with minimal leverage and a strong equity ratio, but negative cash flow performance raises liquidity concerns.

Income Statement

The company has shown a significant increase in revenue over the past year, with a revenue growth rate of 171.7%. However, profitability remains a challenge as evidenced by the negative net profit margin of -141.5% and consistently negative EBIT and EBITDA margins. The gross profit margin is relatively strong at 68.1%, indicating good control over direct costs, but overall profitability is heavily impacted by high operating expenses.

Balance Sheet

The balance sheet exhibits financial stability with a low debt-to-equity ratio of 0.01, suggesting minimal leverage. However, the return on equity is negative at -54.6%, reflecting the company's struggle to generate profits from shareholder investments. The equity ratio stands at 81.7%, indicating a strong equity position relative to total assets, which provides some financial resilience.

Cash Flow

Cash flow performance is weak, with a negative operating cash flow to net income ratio, indicating that the company is not generating enough cash from operations to cover its net income loss. Free cash flow is also negative, and the free cash flow growth rate is -113.7%, showing a declining trend in cash available after capital expenditures.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	4.90M	1.80M	765.19K	145.78K	2.52M
Gross Profit	3.34M	1.31M	523.50K	94.70K	1.83M
EBITDA	-6.88M	-3.80M	-3.08M	-8.33M	-3.17M
Net Income	-6.94M	-3.79M	-2.85M	-8.38M	-2.93M
Balance Sheet
Total Assets	15.55M	21.99M	24.86M	27.05M	6.20M
Cash, Cash Equivalents and Short-Term Investments	11.66M	18.99M	22.11M	25.05M	3.25M
Total Debt	173.50K	189.09K	209.79K	20.50K	61.10K
Total Liabilities	2.84M	2.37M	1.68M	1.16M	558.25K
Stockholders Equity	12.71M	19.62M	23.18M	25.90M	5.64M
Cash Flow
Free Cash Flow	-5.88M	-2.50M	-3.14M	-4.09M	-3.17M
Operating Cash Flow	-5.88M	-2.49M	-3.13M	-4.08M	-3.16M
Investing Cash Flow	327.56K	-2.74M	-10.05K	-6.63K	-864.00
Financing Cash Flow	829.00	-35.02K	-36.26K	26.49M	1.17M

Immuron Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRN, the sentiment is Negative. The current price of 1.75 is below the 20-day moving average (MA) of 1.77, below the 50-day MA of 1.77, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.05 is Neutral, neither overbought nor oversold. The STOCH value of 37.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMRN.

Immuron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
PRTG	48 Neutral	$13.90M	―	-194.84%	―	―	48.91%
IMRN	46 Neutral	$12.41M	―	-52.79%	―	82.77%	-87.95%
RLMD	41 Neutral	$23.86M	―	-160.26%	―	―	19.21%
CTXR	38 Underperform	$18.44M	―	-60.06%	―	―	8.99%
BTAI	37 Underperform	$10.96M	―	82.91%	―	64.20%	73.71%
HOOK	37 Underperform	$11.87M	―	-105.79%	―	-82.54%	-12.53%